scorecardresearch
Saturday, Feb 04, 2023
Advertisement
Premium

HC bars Glenmark from selling anti-diabetes medicine

The court of Justice S Ravindra Bhat and Justice Najmi Waziri issued the injunction, directing Glenmark to stop supply of the drugs.

Anti-diabetes drugs, Zita and Zitamet, are set to go off the market in two weeks, with the Delhi High Court on Friday issuing an injunction against generic drug manufacturer Glenmark on a patent infringement suit filed by US- based drug major Merck Sharp and Dohme (MSD).

The court of Justice S Ravindra Bhat and Justice Najmi Waziri issued the injunction, directing Glenmark to stop supply of the drugs. While, Glenmark can sell the products that are already with distributors and retailers, it is not allowed to put any further products on the market.

The court, in its 81 page order, however, held that prima facie, MSD had been able to show patent infringement, but has noted that the final decision on the issue of patent rights could only be taken after proper trial.

Subscriber Only Stories
UPSC Essentials | Weekly news express with MCQs: Adani-Hindenburg saga, M...
Anti-science movement is political but medicine also hasn’t conveyed its ...
In Jharkhand’s tribal villages, an online marketplace for local produce
Delhi Confidential: Mansukh Mandaviya gives a shout out to youngest Mitra

First published on: 21-03-2015 at 01:39 IST
Next Story

Footfall falls as agri equipment makers boycott kisan mela

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement
close